Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tripeptide
Cartalax is a marketed name for the tripeptide AED, studied in cartilage, connective-tissue, and cell-aging models.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Cartalax is a marketed name for AED, a three-amino-acid peptide studied in cartilage, connective-tissue, and cell-aging models. It is not an approved joint treatment.
Researchers use cultured human cells to ask whether AED changes markers involved in cartilage development or maintenance. That is an early biological question, not a test of pain or joint function.
In cultured human mesenchymal stem cells from older donors, AED altered markers associated with cartilage differentiation. Other laboratory work explored related changes in human cells. No administered-human study was located measuring joint symptoms, cartilage structure, mobility, or clinical safety.
Human absorption, delivery to joints, target exposure, structural effects, symptom relief, comparative effectiveness, product consistency, interactions, and long-term safety remain unknown. A cell-marker change cannot establish that a joint is repaired.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research exposed cultured human mesenchymal stem cells from older donors to AED and measured markers related to cartilage differentiation.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Cell and tissue-model evidence; no controlled administered-human outcome trial located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether the peptide reaches joint tissues in humans and produces structural or symptomatic outcomes without important harms.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Human cells were studied outside the body; participants were not treated. Marker changes cannot establish joint delivery, cartilage repair, symptom relief, clinical safety, or a transferable administration pattern. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Human-derived cells have been studied in vitro; no clinical administration study was located.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether the peptide reaches joint tissues in humans and produces structural or symptomatic outcomes without important harms.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
AED experiments report changes in gene expression and chondrogenic markers in cultured cells. Those findings do not show that administered Cartalax repairs human cartilage.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
In vitro human-cell study
Human mesenchymal stem cells
AED altered chondrogenic differentiation markers in cultured human mesenchymal stem cells from older donors.
Study administration: Not stated in the current record.
Limitations: Cultured-cell outcome; no administered-human structural or symptom evidence.
Human-cell culture study
Population not stated.
Endpoints were not fully described in the current record.
Laboratory work explored peptide-associated changes in cultured human cells.
Study administration: Not stated in the current record.
Limitations: Mechanistic laboratory evidence only.
Safety snapshot
Current evidence cannot yet resolve: Whether the peptide reaches joint tissues in humans and produces structural or symptomatic outcomes without important harms.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved Cartalax/AED product. Whether the peptide reaches joint tissues in humans and produces structural or symptomatic outcomes without important harms.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 37782646
PMID 25051766